How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
treatment of advanced squamous cell carcinoma of the anal canal, supported by Phase 3 POD1UM-303/InterAACT2 data showing improved progression-free survival and no new safety signals. This second European indication for Zynyz broadens Incyte's immuno-oncology footprint and underscores how well-executed late-stage trials can translate into meaningful label expansion. We'll now examine how this new European approval for Zynyz in advanced anal cancer reshapes Incyte's investment narrative and risk profile. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it . Find the list for free. Incyte Investment Narrative Recap To own Incyte, you need to believe that it can gradually reduce its dependence on Jakafi by turning late stage assets like Zynyz into durable, multi indication franchises. The new European approval in anal cancer supports that diversification effort, while the recent FDA Complete Res
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.MarketBeat
- Incyte Announces Executive Leadership AppointmentsBusiness Wire
- Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.MarketBeat
- Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
- Incyte: An Undervalued Healthcare Gem [Seeking Alpha]Seeking Alpha
INCY
Earnings
- 2/10/26 - Beat
INCY
Sec Filings
- 3/26/26 - Form 8-K
- 3/19/26 - Form 4
- 3/17/26 - Form 144
- INCY's page on the SEC website